Riskpilot← Back to searchSign inGet full accessCaviTreat AB
ABActiveOrg 5593807331Fortvägen 100Research and experimental development on natural sciences and engineering · NACE 7210Est. 20221-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
-136% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -33K
-141% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -34K | -136% |
| Net profit | SEK -33K | -141% |
| Total assets | SEK 30K | -78% |
| Equity | SEK 30K | -68% |
| Employees | — | — |
Legal name
CaviTreat AB
Org number
5593807331
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 maj 2022
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att bedriva utveckling, tillverkning, marknadsföring och försäljning av system och utrustning för vatten rening och vatten behandling, äga och förvalta fast och lös egendom samt därmed förenlig verksamhet. Bolaget ska också bedriva konsultverksamhet inom hydrodynamik teknologi, akustik och kavitation teknik, medicinsk teknik och Life Science, speciellt rörande utveckling av produkter från forskning och innovation samt därmed förenlig verksamhet.
Address
Fortvägen 100
Email
dmitry.grishenkov@cavitreat.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | — | 100 | 0 |
| Staff expenses | — | — | — |
| EBITDA | 0 | 96 | −34 |
| Depreciation & amort. | — | — | — |
| EBIT | 0 | 96 | −34 |
| Net financials | — | 1 | 1 |
| Profit before tax | 0 | 97 | −33 |
| Tax | — | −18 | — |
| Net profit | — | 80 | −33 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | — | 135 | 30 |
| Equity | — | 93 | 30 |
| Long-term debt | — | — | — |
| Short-term debt | — | 43 | 0 |
| Total debt | — | 43 | — |
EBITDA margin
-3435400.0%
This company
15.8%
Market median
-21743138% vs market
20222024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20222024
Return on equity
-110.4%
This company
18.4%
Market median
-700% vs market
20222024
Net profit margin
-3286100.0%
This company
8.1%
Market median
-40569236% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CaviTreat AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morteza Ghorbani | Board of Directors | 0 companies |
| Dmitry Grishenkov | Chairman | 0 companies |
| Anna Galutskaya | Deputy Board Member | 0 companies |